Tarsons Products enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,617	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
23.2	23.2	25.1	17.1	—
383	383	329	257	80.7
1,977	—	—	—	—
359	359	303	240	—
₹371.51	—	—	—	—

1,017	1,017	959	870	650
37.6%	37.6%	34.3%	29.5%	12.4%
0.19×	—	—	—	—

4.48×	—	—	—	—
16.58×	—	—	—	—
126.75×	—	—	—	—
441	423	392	296	—
119	118	111	99.8	—
15.6	21.4	48.2	59.4	—
—	118	114	103	75.6
−7.1	−7.1	−37.5	−81.6	−114
—	−15.1	−43.8	−84.5	—
—	126	152	184	190

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TARSONS₹303.95

Tarsons Products Limited

· Pharma & Health

₹ CrorePeersFISCHER LAXMIDENTL FABTECH GKBMcap ₹1,617 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,617.2
- Cash, Equiv & ST Investments	—	17.1	25.1	23.2	23.2
+ Total Debt	80.7	256.8	328.6	382.6	382.6
Enterprise Value	—	—	—	—	1,976.6
Net Debt (memo)	—	239.7	303.4	359.4	359.4
EV per Share	—	—	—	—	371.51

Total Capital	650.0	869.6	958.8	1,017.3	1,017.3
Total Debt/Total Capital	12.41	29.53	34.27	37.61	37.61
Total Debt/EV	—	—	—	—	0.19

EV/Sales	—	—	—	—	4.48
EV/EBITDA	—	—	—	—	16.58
EV/EBIT	—	—	—	—	126.75
Reference Items — Trailing FY Values
Sales	—	296.4	392.4	422.5	441.4
EBITDA	—	99.8	110.7	117.9	119.2
EBIT	—	59.4	48.2	21.4	15.6
Operating Cash Flow	75.6	102.7	114.2	118.5	—
Free Cash Flow	-114.4	-81.6	-37.5	-7.1	-7.1
FCFF (free cash flow to the firm)	—	-84.5	-43.8	-15.1	—
Capital Expenditure	190.0	184.3	151.7	125.6	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.